Journal of Ovarian Research最新文献

{"title":"Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report.","authors":"Yong Wu, Lingfang Xia, Chunyan Song, Xiaojun Chen, Xiaohua Wu","doi":"10.1186/s13048-025-01628-z","DOIUrl":"10.1186/s13048-025-01628-z","url":null,"abstract":"<p><p>Ovarian cancer, colloquially termed the \"king of gynecological cancers,\" presents significant diagnostic and therapeutic challenges due to its covert nature. It ranks as the deadliest gynecologic malignancy with a disheartening 5-year survival rate below 40%. Standard therapeutic protocols for newly diagnosed patients encompass cytoreductive surgery followed by neoadjuvant or adjuvant platinum-based chemotherapy. Despite initial chemotherapeutic responses, recurrence is common, affecting up to 80% of patients, with nearly all developing eventual resistance to chemotherapy regimens. This case report highlights an Aisan patient with ovarian cancer, who exhibited tolerance, recurrence, and progression after several prior lines of treatment. The application of Mirvetuximab Soravtansine, facilitated by positive FRα expression identified through IHC analysis, notably reduced tumor lesions and CA125 levels, achieving a complete response and maintaining low CA125 levels during treatment, underscoring its efficacy in treating platinum-resistant recurrent ovarian cancer.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"43"},"PeriodicalIF":3.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ameliorative effect of Fagonia indica-coated chitosan nanoparticles on the ovulatory pattern in PCOS rat model.","authors":"Threem Zia, Irfana Liaqat, Khawar Ali Shahzad, Mushtaq Hussain Lashari, Dalia Fouad, Farid S Ataya, Saman Alam, Areeba Saeed","doi":"10.1186/s13048-025-01635-0","DOIUrl":"10.1186/s13048-025-01635-0","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovarian syndrome (PCOS) with wide-range prevalence, affecting 5-18% of females of reproductive age, and its substantive role as a primary etiological factor in anovulatory infertility, with up to 80% of such cases attributed to this syndrome having particular significance.</p><p><strong>Objectives: </strong>The current research delineates the outcomes of a meticulous inquiry into the efficacy of Fagonia indica-coated chitosan nanoparticles (FICNPs) in ameliorating the prevalent and clinically consequential PCOS in female Wistar rats.</p><p><strong>Methodology: </strong>FICNPs were synthesized by using a methanolic extract of F. indica and chitosan via the ion gelatin method. The nuanced interplay of hormonal profiles, ovarian histology, and miRNA expression in response to FICNPs intervention was investigated. Notable findings include an obvious decrease in luteinizing (LH) and testosterone hormone levels with high-dose FICNPs-treated subjects (100 mg/kg) compared to their untreated counterparts.</p><p><strong>Results: </strong>Follicle-stimulating hormone (FSH) and prolactin levels were markedly decreased in the untreated PCOS rat models, whereas, histopathological examination revealed augmented oocyte diameters in FICNP-treated rats, suggesting pronounced improvements in ovarian morphogenesis and follicular maturation. Additionally, real-time quantitative PCR analysis revealed disparate miRNA expression profiles, prominently implicating rno-miR-30c-2-3p, rno-miR-146b-5p, rno-miR-486, and rno-miR-3586-3p in the therapeutic efficacy of FICNPs. Notably, the progeny of FICNPs-treated subjects (F1 generation) showed normalized ovulatory activity, substantiating the sustained therapeutic potential of FICNPs.</p><p><strong>Conclusion: </strong>Collectively, these findings underscore the auspicious promise of FICNPs as a paradigm-shifting therapeutic modality for mitigating the complex pathophysiology of PCOS, thereby addressing its formidable prevalence and clinical import, with the potential to surpass conventional pharmacotherapy modalities.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"44"},"PeriodicalIF":3.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SRC involves in lysosomal function and regulates ferroptosis in polycystic ovary syndrome.","authors":"Tianmei Wang, Xin Chen, Cong Li","doi":"10.1186/s13048-025-01637-y","DOIUrl":"10.1186/s13048-025-01637-y","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of polycystic ovary syndrome (PCOS) is still unknown, so finding the molecular mechanisms of pathogenesis is crucial in PCOS.</p><p><strong>Methods: </strong>The GSE34526 dataset from the Gene Expression Omnibus (GEO) database was used to screen biomarkers in this study. KEGG enrichment analysis of GSE34526 was performed using Gene Set Enrichment Analysis (GSEA). The differentially expressed genes(DEGs) were screened and analyzed for lysosome-related genes. Subsequently, further KEGG and GO analyses were performed, and it was found that it was enriched in the ferroptosis pathway, and then the ferroptosis-related differential genes were obtained. The genes at the core position were obtained by the Protein-Protein Interaction(PPI) network. We then focused our attention on SRC and verified the differential expression of SRC in ovarian tissues of hyperandrogenemic, hyperlipemic and control groups, as well as the differences in conception rate and litter rate of each group by rat test.</p><p><strong>Results: </strong>GSEA analysis of the gene dataset GSE34526 revealed that LYSOSOME was significantly enriched in the PCOS group. There were 188 lysosome-related differentially expressed genes(LRDEGs) in granulosa cells from patients with PCOS, and 41 ferroptosis-related differentially expressed genes(FRDEGs). It was found that six of these genes, SRC, NCF2, SLC2A8, FTL, SLC2A6, SLC3A2, were present in all three datasets. SRC was the top ranked gene in the PPI network of FRDEGs.As verified by the rat model, the expression of SRC in the ovarian tissues of the hyperandrogenemic group was significantly higher than that of the control group (P=0.004) and the hyperlipemic group (P=0.002).</p><p><strong>Conclusion: </strong>SRC, as an important gene involved in lysosomal function and regulating ferroptosis, is expected to be a potential target for PCOS.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"42"},"PeriodicalIF":3.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of systemic immune inflammation index for ovarian cancer: An updated systematic review and meta-analysis.","authors":"Boliang Chu, Yingying Chen, Jiewei Pan","doi":"10.1186/s13048-025-01626-1","DOIUrl":"10.1186/s13048-025-01626-1","url":null,"abstract":"<p><strong>Objective: </strong>Several inflammatory indices have been used to assess the prognosis of ovarian cancer, with variable results. This review assessed whether the systemic immune inflammation index (SII) can predict outcomes in patients with ovarian cancer.</p><p><strong>Methods: </strong>Embase, PubMed, CENTRAL, Web of Science, and Scopus databases were searched by the two reviewers from inception to 15th October 2024 for studies assessing the relationship between SII and overall survival (OS) or disease-free survival (DFS).</p><p><strong>Results: </strong>Ten studies with eleven cohorts were included. Pooled analysis showed that higher SII was a significant predictor of poor OS (HR: 2.35 95% CI: 1.56, 3.55 I² = 88%) and worse DFS (HR: 2.51 95% CI: 1.71, 3.67 I² = 80%) after ovarian cancer. Sensitivity analysis failed to change the significance of the results. No publication bias was noted. Most results remained significant on subgroup analyses based on location, sample size, FIGO stage, treatment, adjusted outcomes, cut-off of SII, method of determining cut-off, and quality score.</p><p><strong>Conclusions: </strong>SII can be a potential predictor of OS and DFS after ovarian cancer. Further studies are required to improve the evidence.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"41"},"PeriodicalIF":3.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of age at menarche and different causes of infertility: a retrospective study of 7634 women undergoing assisted reproductive technology.","authors":"Miaomiao Ban, Jiejing Jiao, Jiayi Zhou, Linlin Cui, Huidan Wang, Zi-Jiang Chen","doi":"10.1186/s13048-025-01629-y","DOIUrl":"10.1186/s13048-025-01629-y","url":null,"abstract":"<p><strong>Background: </strong>Infertility has become a world-wide public health problem. To identify women in a high-risk of infertility at an early stage when more treatments are available, early risk factors such as age at menarche (AAM) are being investigated. AAM is often used in epidemiological studies as a marker of the timing of pubertal development and the onset of the hypothalamic-pituitary-ovarian axis functions. Therefore, our study aimed to elucidate the association of AAM and different infertility causes in women undergoing assisted reproductive technology.</p><p><strong>Methods: </strong>A total of 7643 women were retrospectively included from the reproductive hospital affiliated with Shandong University between January 2017 and December 2019. Multivariate logistic regression models and restricted cubic spline (RSC) were performed to analyze the relationship between AAM and different infertility causes. Information on variables was obtained from medical records.</p><p><strong>Results: </strong>Compared with primary infertility, secondary infertility would 7.7% increase risk with each one-year increase in menarche age after adjusted odds ratio (OR) [95% confidence interval (CI)], 1.077 (1.036, 1.119). In primary infertility group, each one-year increase in menarche age corresponded with a 16.7% increase in PCOS risk OR (95% CI), 1.218 (1.138, 1.303). AAM of women with DOR were significantly decreased in primary and secondary infertility group [OR (95% CI), 0.832 (0.716, 0.965) and OR (95% CI), 0.720 (0.603, 0.859)], respectively compared with the reference group. Moreover, there is a non-linear dose-response relationship between DOR (P < 0.001) with AAM.</p><p><strong>Conclusion: </strong>This study demonstrates a significant impact of AAM on endocrine-related infertility in women. Further research on the relationship between the onset of menarche and the pathogenesis of infertility is warranted.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"40"},"PeriodicalIF":3.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring new frontiers in oncofertility preservation: a case of ovarian stimulation during pregnancy.","authors":"Parisa Pirooznia, Esmat Mashhadi Meighani, Firouzeh Ghaffari","doi":"10.1186/s13048-025-01615-4","DOIUrl":"10.1186/s13048-025-01615-4","url":null,"abstract":"<p><strong>Background: </strong>The standard treatment for Pregnancy-Associated Breast Cancer (PABC) includes surgery and neoadjuvant chemotherapy, which can impair fertility, emphasizing the critical need for fertility preservation in these patients. This case report discusses a breast cancer patient who was found to be pregnant shortly after starting treatment. Despite the pregnancy and increased levels of βHCG and progesterone, the ovarian stimulation cycle yielded a satisfactory number of mature oocytes and high-quality embryos.</p><p><strong>Case presentation: </strong>A 40-year-old woman, G1Ab1 (Gravida1Abortion1), who was diagnosed with Invasive Ductal Carcinoma with negative receptors (Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2) was referred to the oncofertility unit of the Royan Infertility Center for fertility preservation prior to the commencement of chemotherapy. Following necessary consultations and procedures, and confirming a negative pregnancy test, a random start letrozole-based protocol was initiated for ovarian stimulation. During the cycle, a positive pregnancy test was encountered. Despite the positive test, the cycle continued, and on day 13 of the cycle, triggering was performed with a GnRH agonist. A puncture was performed 36 h later, yielding 12 oocytes and 8 embryos.</p><p><strong>Conclusion: </strong>This case highlights the feasibility of adapting random-start ovarian stimulation protocols during pregnancy, warranting further investigation in similar clinical scenarios.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"39"},"PeriodicalIF":3.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interference with CHD1L inhibits the malignant progression and enhances cisplatin sensitivity of ovarian cancer cells by binding PLK1.","authors":"Kun Qiao, Yuanxiazi Guan, Wenjing Xing","doi":"10.1186/s13048-024-01582-2","DOIUrl":"10.1186/s13048-024-01582-2","url":null,"abstract":"<p><strong>Background: </strong>Chromodomain helicase/ATPase DNA-binding protein 1-like gene (CHDIL) is an oncogene with abnormal expression in ovarian cancer (OC), but its regulatory role in the malignant biological properties of OC cells and its mechanisms have not been reported.</p><p><strong>Methods: </strong>In this study, CHD1L and polo-like Kinase 1 (PLK1) expression in OC tissues and OC cell lines was analyzed. After CHD1L silencing, CAOV-3 cell proliferation and apoptosis were detected by CCK8 assay, EDU and TUNEL staining. Flow cytometry was used to detect cell cycle. CCK8 assay and TUNEL were used to detect the role of CHD1L in the sensitivity of OC cells to cisplatin. In addition, the abilities of CAOV-3 cell migration and invasion were evaluated using wound healing assay and transwell assay. Next, the binding between CHD1L and PLK1 was investigated using co-immunoprecipitation assay. Then, PLK1 was overexpressed to perform the rescue experiments to analyze the regulation mechanism of CHD1L on OC development and cisplatin sensitivity. Moreover, the transplantation tumor model of CAOV-3 cells in nude mice was established to explore the antineoplastic effect of CHD1L downregulation in vivo.</p><p><strong>Results: </strong>CHD1L was highly expressed in OC tissues and OC cells. Interference with CHD1L significantly inhibited proliferation, promoted apoptosis, induced cycle arrest, suppressed migration and invasion as well as enhanced the sensitivity of CAOV-3 cells to cisplatin. Additionally, CHD1L could interact with PLK1. PLK1 upregulation restored the impacts of CHD1L knockdown on the proliferation, apoptosis, cycle arrest, migration, invasion and the sensitivity of OC cells to cisplatin. It could be also found that CHD1L knocked down limited the tumor volume, downregulated PLK1, Ki67 and cleaved caspse3 expression.</p><p><strong>Conclusion: </strong>Taken together, interference with CHD1L inhibited the malignant progression and enhanced cisplatin sensitivity of OC cells by binding PLK1.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"38"},"PeriodicalIF":3.8,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it time to abandon staging surgery and prolonged follow-up in patients with primary adult-type granulosa cell tumor?","authors":"Geertruid J Brink, Jolijn W Groeneweg, Ariane A Sickinghe, Hans W Nijman, Luc R C W van Lonkhuijzen, Christianne A R Lok, Jurgen M J Piek, Eva Maria Roes, Cornelis D de Kroon, Ward Hofhuis, Geertruida N Jonges, Eelke H Gort, Petronella O Witteveen, Ronald P Zweemer","doi":"10.1186/s13048-025-01622-5","DOIUrl":"10.1186/s13048-025-01622-5","url":null,"abstract":"<p><strong>Background: </strong>As current literature does not provide sufficient data to support clear guidelines in patients with a rare adult-type granulosa cell tumor, we aim to investigate: (1) whether additional staging surgery following primary surgical treatment is necessary; (2) how long standard follow-up should be and (3) risk factors for disease recurrence.</p><p><strong>Methods: </strong>A national multicenter prospective study was initiated in April 2018. Patients with suspected or confirmed adult-type granulosa cell tumor were eligible. Data on staging, follow-up and risk factors were both retrospectively and prospectively collected from medical records, and patients were followed until April 2024 or until death. Descriptive statistical analysis and survival analysis were performed using Cox regression methods and Kaplan-Meier analyses.</p><p><strong>Results: </strong>In total, 208 patients with histopathologically confirmed adult-type granulosa cell tumor were included, with a median follow-up of 5.5 years (IQR: 2.2-12.3 years). Vaginal bleeding and abdominal pain were the most common symptoms at diagnosis. Median time until first recurrence was 4.2 years (range 2 months- 32 years). Additional staging surgery did not reduce the risk of recurrence. During follow-up, most patients had no symptoms at the time of detection of recurrence. No difference in overall survival was found between patients who were diagnosed with a recurrence during follow-up, and those who were no longer in follow-up and presented with symptoms.</p><p><strong>Conclusions: </strong>Staging surgery does not improve recurrence free survival in patients with adult-type granulosa cell tumor. Our results suggest that adult-type granulosa cell tumor patients can be discharged from follow-up of adult-type granulosa cell tumor after five years.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"37"},"PeriodicalIF":3.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TAM-derived exosomal miR-589-3p accelerates ovarian cancer progression through BCL2L13.","authors":"Jianqing Wang, Yan Zhu, Yang He, Weiwei Shao","doi":"10.1186/s13048-025-01618-1","DOIUrl":"10.1186/s13048-025-01618-1","url":null,"abstract":"<p><strong>Background: </strong>Tumor-associated macrophages (TAM) are critical elements of intercellular communication in tumor microenvironment (TME), and exosomes are key mediators between tumor cells and the TME. According to previous reports, miRNAs exert a pivotal role in ovarian cancer (OC) development. The purpose of this work was to explore the function of TAM-derived exosomal miR-589-3p in OC development and elucidate the underlying molecular mechanisms.</p><p><strong>Methods: </strong>First, peripheral blood mononuclear cells (PBMC) were treated with IL-4 and IL-13 to polarize them into M2-type macrophages. Exosomes were separated from M2-type macrophages, and the physical properties of exosomes were evaluated using transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). Next, quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) was applied to examine the expression of relevant genes. Subsequently, Targetscan and miRDB were utilized to predict miR-589-3p target genes, and then the interaction between miR-589-3p and BCL2L13 was verified by dual luciferase assay and RNA Binding Protein Immunoprecipitation (RIP) assay. Finally, Cell Counting Kit-8 (CCK-8) and flow cytometry experiments were employed to explore the changes in the proliferative and apoptotic abilities of OC cells.</p><p><strong>Results: </strong>In this research, we demonstrated that TAM-derived exosomes facilitated OC cell proliferation and suppressed OC cell apoptosis. Then, qRT-PCR results indicated that miR-589-3p were markedly elevated after co-culture of TAM-derived exosomes with OC cells. In addition, we discovered that miR-589-3p was bound to BCL-2-like protein 13 (BCL2L13), which was confirmed through luciferase assay and RIP assay. Furthermore, functional analysis displayed that TAM-derived exosomes treated with miR-589-3p inhibitor attenuated the promotion of OC cell progression by exosomes.</p><p><strong>Conclusion: </strong>TAM-derived exosomal miR-589-3p enhanced OC progression through BCL2L13, which offers a novel for OC therapy.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"36"},"PeriodicalIF":3.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation.","authors":"Pingping Su, Chao Chen, Yun Sun","doi":"10.1186/s13048-025-01621-6","DOIUrl":"10.1186/s13048-025-01621-6","url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterized by elevated androgen levels, ovarian cysts, and impaired ovulation in females. This condition is closely linked with various reproductive health issues and has significant impacts on endocrine and metabolic pathways. Patients with PCOS commonly exhibit hyperandrogenaemia and insulin resistance, leading to complications such as acne, hirsutism, weight fluctuations, and metabolic disturbances, as well as an increased risk for type 2 diabetes, cardiovascular disease, and endometrial cancer. Although extensive research has identified several mechanistic aspects of PCOS, a thorough understanding of its pathophysiology remains incomplete. This review aims to provide a detailed analysis of the physiological and pathological aspects of PCOS, covering endocrine, metabolic, and inflammatory dimensions, to better elucidate its etiological framework.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"34"},"PeriodicalIF":3.8,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}